Common Contracts

EX-4.4 3 a2226129zex-4_4.htm EX-4.4 EXECUTION VERSION CONFIDENTIAL SECOND AMENDED & RESTATED INVESTORS’ RIGHTS AGREEMENT Page Schedule A - Schedule of Investors Schedule B - Schedule of Key Holders Schedule C - Schedule of Initial Investors Schedule D...

Investors’ Rights Agreement • May 5th, 2020 • New York

• Contract Type
  Investors’ Rights Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Investors’ Rights Agreement”), is made as of the 21st day of April, 2015, by and among BeiGene, Ltd., a Cayman Islands exempted company (the “Company”); each of the shareholders listed on Schedule A hereto (the “Investors”); each of the shareholders listed on Schedule B hereto (the “Key Holders”); and each of the shareholders listed on Schedule C hereto (the “Initial Investors”).

SECOND AMENDED & RESTATED INVESTORS’ RIGHTS AGREEMENT

Investors’ Rights Agreement • October 16th, 2015 • BeiGene, Ltd. • Pharmaceutical preparations • New York

• Contract Type
  Investors’ Rights Agreement
• Filed
  October 16th, 2015
• Company
  BeiGene, Ltd.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Investors’ Rights Agreement”), is made as of the 21st day of April, 2015, by and among BeiGene, Ltd., a Cayman Islands exempted company (the “Company”); each of the shareholders listed on Schedule A hereto (the “Investors”); each of the shareholders listed on Schedule B hereto (the “Key Holders”); and each of the shareholders listed on Schedule C hereto (the “Initial Investors”).

SECOND AMENDED & RESTATED INVESTORS’ RIGHTS AGREEMENT

Investors’ Rights Agreement • August 28th, 2015 • BeiGene, Ltd. • Pharmaceutical preparations • New York

• Contract Type
  Investors’ Rights Agreement
• Filed
  August 28th, 2015
• Company
  BeiGene, Ltd.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

THIS SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Investors’ Rights Agreement”), is made as of the 21st day of April, 2015, by and among BeiGene, Ltd., a Cayman Islands exempted company (the “Company”); each of the shareholders listed on Schedule A hereto (the “Investors”); each of the shareholders listed on Schedule B hereto (the “Key Holders”); and each of the shareholders listed on Schedule C hereto (the “Initial Investors”).